Fresenius Sues Baxter to Block Copies of Naropin Anesthetic

Fresenius said Baxter’s proposed generic version of Naropin infringes four patents for the injectable drug, used as an anesthetic during surgery or to ease labor pains.

• Fresenius is seeking a court order blocking copies and the use of any infringing compound until patents have expired, and cash compensation if copies are made before then, according to complaint filed Friday in federal court in Wilmington, Delaware
• Patents expire in May 2023, May 2024, October 2025 and November 2026: supplemental filing
• CASE: Fresenius Kabi USA v. Baxter Healthcare, 21-cv-1040, U.S. District Court, District of Delaware (Wilmington)

To contact the reporter ...